LT3897833T - Apol1 inhibitoriai ir jų panaudojimo būdai - Google Patents

Apol1 inhibitoriai ir jų panaudojimo būdai

Info

Publication number
LT3897833T
LT3897833T LTEPPCT/US2019/066746T LTUS2019066746T LT3897833T LT 3897833 T LT3897833 T LT 3897833T LT US2019066746 T LTUS2019066746 T LT US2019066746T LT 3897833 T LT3897833 T LT 3897833T
Authority
LT
Lithuania
Prior art keywords
apol1
inhibitors
methods
apol1 inhibitors
Prior art date
Application number
LTEPPCT/US2019/066746T
Other languages
English (en)
Inventor
Michael Brodney
Kevin Gagnon
Kan-Nian Hu
Ales Medek
Peter Rose
Yi Shi
Muna SHRESTHA
Faith WITKOS
Jingrong Cao
Jon H. Come
Leslie A. DAKIN
Francois Denis
Warren A. DORSCH
Anne FORTIER
Martine Hamel
Elaine B. Krueger
Brian Ledford
Suganthini S. Nanthakumar
Olivier Nicolas
Camil SAYEGH
Timothy J. SENTER
Tiansheng Wang
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of LT3897833T publication Critical patent/LT3897833T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
LTEPPCT/US2019/066746T 2018-12-17 2019-12-17 Apol1 inhibitoriai ir jų panaudojimo būdai LT3897833T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862780667P 2018-12-17 2018-12-17
PCT/US2019/066746 WO2020131807A1 (en) 2018-12-17 2019-12-17 Inhibitors of apol1 and methods of using same

Publications (1)

Publication Number Publication Date
LT3897833T true LT3897833T (lt) 2026-04-27

Family

ID=69182627

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2019/066746T LT3897833T (lt) 2018-12-17 2019-12-17 Apol1 inhibitoriai ir jų panaudojimo būdai

Country Status (29)

Country Link
US (3) US11618746B2 (lt)
EP (1) EP3897833B1 (lt)
JP (1) JP7573528B2 (lt)
KR (2) KR20260020195A (lt)
CN (1) CN113453760B (lt)
AR (1) AR116913A1 (lt)
AU (1) AU2019405477B2 (lt)
CA (1) CA3121910A1 (lt)
CL (1) CL2021001561A1 (lt)
CO (1) CO2021009053A2 (lt)
CR (1) CR20210383A (lt)
DK (1) DK3897833T3 (lt)
DO (1) DOP2021000116A (lt)
EC (1) ECSP21052184A (lt)
FI (1) FI3897833T3 (lt)
IL (2) IL283592B2 (lt)
JO (3) JOP20210131A1 (lt)
LT (1) LT3897833T (lt)
MA (1) MA54538B1 (lt)
MX (1) MX2021007152A (lt)
PE (1) PE20212302A1 (lt)
PT (1) PT3897833T (lt)
SA (1) SA521422270B1 (lt)
SG (1) SG11202105769XA (lt)
SM (1) SMT202600169T1 (lt)
TW (1) TWI848031B (lt)
UA (1) UA128375C2 (lt)
UY (1) UY38514A (lt)
WO (1) WO2020131807A1 (lt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283592B2 (en) 2018-12-17 2025-08-01 Vertex Pharma Inhibitors of apol1 and methods of using same
EP4097083A1 (en) * 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20210246121A1 (en) * 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
CN115209894B (zh) * 2020-03-06 2025-05-02 弗特克斯药品有限公司 治疗apol-1依赖性局灶节段性肾小球硬化的方法
CA3185144A1 (en) * 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CN116157393A (zh) 2020-06-12 2023-05-23 弗特克斯药品有限公司 Apol1的抑制剂及其用途
EP4165036A1 (en) * 2020-06-12 2023-04-19 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
UY39395A (es) * 2020-08-26 2022-03-31 Vertex Pharma Inhibidores de apol1 y métodos para usar los mismos
WO2022178315A1 (en) 2021-02-19 2022-08-25 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
KR20240051990A (ko) * 2021-08-26 2024-04-22 버텍스 파마슈티칼스 인코포레이티드 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
JP2024544060A (ja) * 2021-11-30 2024-11-27 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１のスピロ環式阻害剤およびこれを使用する方法
KR20240149461A (ko) * 2022-01-18 2024-10-14 메이즈 테라퓨틱스, 인코퍼레이티드 Apol1 저해제 및 사용 방법
CA3251050A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE
WO2023194895A1 (en) 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Pyrrol derivatives as inhibitors of apolipoprotein l-1
EP4573077A1 (en) * 2022-08-19 2025-06-25 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
WO2025006262A1 (en) * 2023-06-29 2025-01-02 Omniab, Inc. Tetracyclic compounds containing a fused indole for treating apol1-mediated chronic kidney disease
GB202401326D0 (en) * 2024-02-01 2024-03-20 Podium Bio Ltd Novel compounds
KR20250122547A (ko) 2024-02-05 2025-08-14 서주사이언티픽 주식회사 AIoT 기반 방사성 동위원소 관리 시스템
WO2026012338A1 (zh) * 2024-07-09 2026-01-15 上海旭成医药科技有限公司 一种APOLs抑制剂

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
ZA977103B (en) 1996-08-09 1999-02-08 Eisai Co Ltd Benzopiperidine derivatives
AU2201699A (en) 1997-12-19 1999-07-12 Eli Lilly And Company Hypoglycemic imidazoline compounds
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
WO2001017965A2 (en) 1999-09-07 2001-03-15 Syngenta Participations Ag Cyanopiperidines as pesticides
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
CA2424222A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
CA2672549A1 (en) 2001-11-14 2003-06-12 Ben-Zion Dolitzky Amorphous and crystalline forms of losartan potassium and process for their preparation
WO2003104180A1 (en) 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
EP1572660B1 (en) 2002-12-20 2011-01-26 X-Ceptor Therapeutics, Inc. Isoquinolinone derivatives and their use as therapeutic agents
EP1663972A1 (en) 2003-09-03 2006-06-07 Galapagos N.V. The claimed invention relates to novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-ht2a receptor-related disorders
ES2414604T3 (es) 2004-03-03 2013-07-22 Eli Lilly And Company Moduladores del receptor nuclear de hormonas esteroides de derivados bicíclicos sustituidos con indol
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
CA2629192A1 (en) 2005-11-22 2007-05-31 Merck & Co., Inc. Indole orexin receptor antagonists
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
EP2086935A1 (de) 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
MX2009006454A (es) 2006-12-22 2009-06-26 Hoffmann La Roche Derivados de espiro-piperidina.
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
JP5323834B2 (ja) 2007-08-17 2013-10-23 エルジー・ライフ・サイエンシーズ・リミテッド 細胞壊死阻害剤としてのインドール化合物
CN105254557A (zh) 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
DK2501704T3 (da) 2009-11-16 2013-10-14 Lilly Co Eli Spiropiperidinforbindelser som oral-1-receptorantagonister
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
WO2014085154A1 (en) 2012-11-27 2014-06-05 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
EP3049405A4 (en) 2013-09-26 2017-03-08 Pharmakea Inc. Autotaxin inhibitor compounds
EP3122726B1 (en) 2014-03-27 2018-08-29 Academisch Medisch Centrum N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
EP3186225A4 (en) 2014-08-27 2018-02-28 The Governing Council of the University of Toronto Cannabinoid type 1 receptor modulators
ES2751623T3 (es) 2014-10-08 2020-04-01 Inst Nat Sante Rech Med Nuevos compuestos de aminopiridina útiles como inhibidores de la prenilación de proteínas
JP2017535545A (ja) 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物
RS61719B1 (sr) 2015-08-27 2021-05-31 Pfizer Biciklična fuzionisana hetaroaril ili aril jedinjenja kao modulatori irak4
EP3414247B1 (en) 2016-02-08 2021-04-21 F. Hoffmann-La Roche AG Spiroindolinones as ddr1 inhibitors
AU2019263176B2 (en) 2018-04-30 2025-02-27 The Trustees Of Indiana University Compounds for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease
IL316397A (en) 2018-05-22 2024-12-01 Ionis Pharmaceuticals Inc Modulators of APOL1 expression
IL283592B2 (en) 2018-12-17 2025-08-01 Vertex Pharma Inhibitors of apol1 and methods of using same
WO2020186220A1 (en) 2019-03-13 2020-09-17 Immunophage Biomedical Co., Ltd. Compounds as inhibitors of macrophage migration inhibitory factor
KR20220130127A (ko) 2019-12-19 2022-09-26 카스마 테라퓨틱스, 인코포레이티드 Trpml 조절제
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20210246121A1 (en) * 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
CN115209894B (zh) 2020-03-06 2025-05-02 弗特克斯药品有限公司 治疗apol-1依赖性局灶节段性肾小球硬化的方法
US20230150980A1 (en) 2020-04-22 2023-05-18 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
CA3185144A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
EP4165036A1 (en) 2020-06-12 2023-04-19 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
CN116157393A (zh) 2020-06-12 2023-05-23 弗特克斯药品有限公司 Apol1的抑制剂及其用途
UY39395A (es) 2020-08-26 2022-03-31 Vertex Pharma Inhibidores de apol1 y métodos para usar los mismos
KR20240051990A (ko) 2021-08-26 2024-04-22 버텍스 파마슈티칼스 인코포레이티드 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
JP2024544060A (ja) 2021-11-30 2024-11-27 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１のスピロ環式阻害剤およびこれを使用する方法
WO2023154310A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
JP2025505644A (ja) 2022-02-08 2025-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤としての４’，５’－ジヒドロスピロ［ピペリジン－４，７’－チエノ［２，３－ｃ］ピラン］誘導体、及びそれを使用する方法
CA3251050A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE
CA3251155A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Spiropiperidine derivatives used as APOL1 inhibitors and their methods of use

Also Published As

Publication number Publication date
IL283592A (en) 2021-07-29
TWI848031B (zh) 2024-07-11
UA128375C2 (uk) 2024-06-26
JP2022515369A (ja) 2022-02-18
CN113453760A (zh) 2021-09-28
SG11202105769XA (en) 2021-07-29
EP3897833A1 (en) 2021-10-27
KR20210116483A (ko) 2021-09-27
CR20210383A (es) 2021-09-22
MA54538B1 (fr) 2026-04-30
ECSP21052184A (es) 2021-08-31
AU2019405477B2 (en) 2025-04-03
US20230271945A1 (en) 2023-08-31
CA3121910A1 (en) 2020-06-25
US11618746B2 (en) 2023-04-04
JP7573528B2 (ja) 2024-10-25
KR20260020195A (ko) 2026-02-10
AR116913A1 (es) 2021-06-23
IL283592B1 (en) 2025-04-01
CL2021001561A1 (es) 2021-11-26
CN113453760B (zh) 2024-05-24
BR112021011564A2 (pt) 2021-08-31
US20250042878A1 (en) 2025-02-06
SMT202600169T1 (it) 2026-05-12
CO2021009053A2 (es) 2021-08-09
TW202039471A (zh) 2020-11-01
US20200377479A1 (en) 2020-12-03
JOP20210131A1 (ar) 2023-01-30
UY38514A (es) 2020-07-31
PE20212302A1 (es) 2021-12-10
SA521422270B1 (ar) 2024-02-18
KR102912203B1 (ko) 2026-01-16
US12060346B2 (en) 2024-08-13
FI3897833T3 (fi) 2026-04-07
AU2019405477A1 (en) 2021-06-24
JOP20210129A1 (ar) 2023-01-30
DK3897833T3 (da) 2026-03-30
IL319575A (en) 2025-05-01
DOP2021000116A (es) 2021-09-30
MA54538A (fr) 2021-10-27
MX2021007152A (es) 2021-11-03
JOP20210130A1 (ar) 2023-01-30
WO2020131807A1 (en) 2020-06-25
PT3897833T (pt) 2026-04-22
EP3897833B1 (en) 2026-02-04
IL283592B2 (en) 2025-08-01

Similar Documents

Publication Publication Date Title
IL283592A (en) Inhibitors of apol1 and methods of using same
IL287751A (en) Kcnt1 inhibitors and methods of use
IL287768A (en) Kcnt1 inhibitors and methods of use
IL282487A (en) Tyk2 inhibitors and uses thereof
IL261606A (en) Inhibitors of transfected menin-mll and methods of use
IL263510A (en) Use of myostatin inhibitors and combination therapies
IL279475A (en) Actonucleotidase inhibitors and methods of using them
IL267291A (en) Actonucleotidase inhibitors and methods of using them
EP3572400A4 (en) EZH2 INHIBITOR AND ITS USE
IL274504A (en) 2ACSS inhibitors and methods of their use
EP3515916C0 (en) SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
IL283782A (en) Anellosomes and methods of use
PL3761980T3 (pl) Związki aminokwasowe i sposoby zastosowania
ZA202407941B (en) Arginase inhibitors and methods of use thereof
IL287973A (en) acss2 inhibitors and methods of their use
IL278989A (en) MASP-2 suppressors and methods of using them
LT3852533T (lt) Piridazinonai ir jų naudojimo būdai
LT3452485T (lt) Arginazės inhibitoriai ir jų terapinis taikymas
LT3151832T (lt) Toninio slopinimo sustiprinimo ir antrinės nemigos gydymo būdai
LT3840837T (lt) Arginazės inhibitoriai ir jų panaudojimo būdai
EP3849664C0 (en) PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
LT3630772T (lt) Pde9 inhibitorių gamybos ir naudojimo būdai
IL286485A (en) Pi4-kinase inhibitors and methods of using the same
HK40049706A (en) Ectonucleotidase inhibitors and methods of use thereof